Public health and company wealthNathan Ford
, London EC1N 8QX
BMJ 326:1296. 2003
Mortality, violence and lack of access to healthcare in the Democratic Republic of CongoMichel van Herp
Disasters 27:141-53. 2003
..Infectious-disease control and treatment are a priority, as is increasing access to health-care. Humanitarian assistance must be increased considerably, especially in rural areas and zones that have been affected directly by conflict...
Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and ThailandNathan Ford
Medecins Sans Frontieres, 522 Mooban Nakorn Thai 14, Ladphrao Soi 101 1, Bangkok 10240, Thailand
AIDS 21:S21-9. 2007
..An informed and engaged civil society is essential to support governments in putting health before trade...
The role of civil society in protecting public health over commercial interests: lessons from ThailandNathan Ford
, Ladphrao, Klongchan Bangkapi, Bangkok, Thailand
Lancet 363:560-3. 2004
Registration problems for antiretrovirals in AfricaNathan Ford
, Khayelitsha, 7784 South Africa
Lancet 367:794-5. 2006
Challenge and co-operation: civil society activism for access to HIV treatment in ThailandNathan Ford
Medecins Sans Frontieres, Bangkok, Thailand
Trop Med Int Health 14:258-66. 2009
..Today, most PHA in Thailand can access treatment, and efforts have shifted to supporting care for excluded populations...
HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in ThailandDavid Wilson
Medecins Sans Frontieres, Ladphrao, Bangkok, Thailand
Trans R Soc Trop Med Hyg 103:601-6. 2009
..When implemented with a patient-centered approach, it can be a very useful tool for psychosocial support...
HIV prevention, care, and treatment in two prisons in ThailandDavid Wilson
, Bangkapi, Bangkok, Thailand
PLoS Med 4:e204. 2007
WHO must defend patients' interests, not industryPaul Cawthorne
, Bangkok 10240, Thailand
Lancet 369:974-5. 2007
Addressing psychosocial needs in the aftermath of the tsunamiKaz de Jong
PLoS Med 2:e179. 2005
Lessons learned during down referral of antiretroviral treatment in Tete, MozambiqueTom Decroo
South African Medical Unit, Medecins Sans Frontieres, Johannesburg, South Africa
J Int AIDS Soc 12:6. 2009
..Down referral can be avoided by initiating patients' antiretroviral treatment at clinic level from the outset...
Do aid agencies have an ethical duty to comply with researchers? A response to RennieRony Zachariah
Medecins Sans Frontieres, 68 Rue de Gasperich, L 1617, Gasperich, Luxembourg
Dev World Bioeth 6:78-80. 2006
....
Ethics of conducting research in conflict settingsNathan Ford
, Johannesburg, South Africa
Confl Health 3:7. 2009
..Special attention needs to be placed on the feasibility and necessity of doing research in conflict-settings, and the harm-benefit ratio for potential research participants...
An integrated approach of community health worker support for HIV/AIDS and TB care in Angónia district, MozambiqueSandrine Simon
, Maputo, Mozambique
BMC Int Health Hum Rights 9:13. 2009
..CONCLUSION: The community health team has several advantages over 'disease-specific' community health worker approaches in terms of accountability, acceptability, and expanded access to care...
Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural LesothoHelen Bygrave
Medecins Sans Frontieres, Morija, Lesotho
PLoS ONE 6:e17609. 2011
..We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho...
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two yearsHelen Bygrave
Medecins Sans Frontieres, Morija, Lesotho
J Acquir Immune Defic Syndr 56:e75-8. 2011
..We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho...
Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in LesothoNathan Ford
Medecins Sans Frontieres, University of Cape Town, South Africa
AIDS 24:2645-50. 2010
..Lesotho has supported earlier initiation since 2008. We assessed outcomes comparing early (CD4 cell counts >200 cells/?l) and late (CD4 cell counts ?200 cells/?l) initiation...
Operative mortality in resource-limited settings: the experience of Medecins Sans Frontieres in 13 countriesKathryn M Chu
Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Arch Surg 145:721-5. 2010
..To determine operative mortality in surgical programs from resource-limited settings...
Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohortNathan Ford
Medecins Sans Frontieres, Cape Town, South Africa
PLoS ONE 5:e10460. 2010
..Previous studies have demonstrated a cross-sectional relationship between antiretroviral adherence and HIV virological suppression. We assessed the predictive value of baseline adherence in determining long-term virological failure...
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohortsNathan Ford
Medecins Sans Frontieres, University of Cape Town, Cape Town, South Africa
AIDS 24:1461-70. 2010
..Data on efavirenz safety in first trimester pregnancy are conflicting. We conducted a systematic review and meta-analysis of the available evidence from observational cohorts...
Slow response to Angola's food crisisNathan Ford
, 124-32 Clerkenwell Road, London EC1R 5DJ, UK
Lancet 360:334-6. 2002
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trialsNathan Ford
Medecins Sans Frontieres, Cape Town, Western Cape, South Africa
Lancet 374:2064-71. 2009
..We did a systematic review and meta-analysis of randomised trials of directly observed versus self-administered antiretroviral treatment...
Improving first-line antiretroviral therapy in resource-limited settingsNathan Ford
Medecins Sans Frontieres, Medical Unit, Cape Town, South Africa
Curr Opin HIV AIDS 5:38-47. 2010
..Newer medicines with greater potency and better safety profiles open the possibility for improving first-line antiretroviral therapy for developing countries...
The first decade of antiretroviral therapy in AfricaNathan Ford
Medecins Sans Frontieres, Geneva, Switzerland
Global Health 7:33. 2011
....
Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaKathryn M Chu
South African Medical Unit, Medecins Sans Frontieres, Johannesburg, South Africa
PLoS ONE 5:e9183. 2010
..One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity...
Surgical care for the direct and indirect victims of violence in the eastern Democratic Republic of CongoKathryn Chu
Medecins Sans Frontieres, 49 Jorrisen St, Braamfontein 2017, Johannesburg, South Africa
Confl Health 4:6. 2010
..In this paper we report on surgical interventions carried out by Médecins sans Frontières in Masisi, North Kivu, Democratic Republic of Congo to contribute to the scarce evidence base on surgical needs in conflict...
When to start antiretroviral therapy in resource-limited settings: a human rights analysisNathan Ford
Medecins Sans Frontieres, Cape Town, South Africa
BMC Int Health Hum Rights 10:6. 2010
....
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS careMartha Bedelu
Medecins Sans Frontieres, Lusikisiki, South Africa
J Infect Dis 196:S464-8. 2007
..Maintaining quality and coverage will require increased resource input from the public sector and full acceptance of creative approaches to implementation, including task shifting and community involvement...
International nurse migration and HIV/AIDSSharonann Lynch
JAMA 300:1024; author reply 1024. 2008
HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the CongoHeather Culbert
, Amsterdam, The Netherlands
PLoS Med 4:e129. 2007
Access to drugs: the case of Abbott in ThailandPaul Cawthorne
Lancet Infect Dis 7:373-4. 2007
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemicDavid Heiden
Department of Ophthalmology and Pacific Vision Foundation, California Pacific Medical Center, San Francisco, California, United States of America
PLoS Med 4:e334. 2007
Treating HIV in the developing world: getting ahead of the drug development curveNathan Ford
Drug Discov Today 12:1-3. 2007
The courage to change the rules: a proposal for an essential health R&D treatyNicoletta Dentico
PLoS Med 2:e14. 2005
Violence in southern SudanVincent Brown
Epicentre, 8 rue Saint Sabin, 75 011 Paris, France
Lancet 359:161. 2002
HIV drug resistanceAlexandra Calmy
N Engl J Med 350:2720-1. 2004
25 years of the WHO essential medicines lists: progress and challengesRichard Laing
Boston University School of Public Health, Boston, MA 02118, USA
Lancet 361:1723-9. 2003
..This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines...
The G8 and access to medicines: no more broken promisesMary Moran
, EC1N 8QX, London, UK
Lancet 361:1578-9. 2003
WHO must continue its work on access to medicines in developing countriesNathan Ford
Lancet 361:3. 2003
Rapid assessment of mortality and malnutrition in AfghanistanPatrice Piola
JAMA 288:1233-4. 2002
HIV/AIDS prevention and treatmentEric Goemaere
Lancet 360:86-7; author reply 87-8. 2002
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the communityArlene Chua
PLoS Med 2:e346. 2005
HIV viral load monitoring in resource-limited regions: optional or necessary?Alexandra Calmy
Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
Clin Infect Dis 44:128-34. 2007
..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
(The Lancet)red: a missed opportunityAlexandra Calmy
Lancet 368:1063. 2006
Scaling up antiretroviral treatment in resource-poor settingsTom Ellman
Lancet 368:445-6. 2006
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohortAlexandra Calmy
MSF, Campaign for Access to Essential Medicines, 78 rue de Lausanne, 1205 Geneva, Switzerland
AIDS 20:1163-9. 2006
..The use fixed-dose combination (FDC) is a critical tool in improving HAART. Studies on the effectiveness of combined lamivudine, stavudine and nevirapine (3TC/d4T/NVP) are scarce...
Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewingNathan Ford
Drug Discov Today 12:349-51. 2007
First round of payments from the Global FundTom Ellman
Lancet 360:262. 2002
XDR-TB in South Africa: detention is not the priorityEric Goemaere
PLoS Med 4:e162. 2007
Drug development for neglected diseases: a deficient market and a public-health policy failurePatrice Trouiller
Centre Hospitalier Universitaire, BP 217, 38043 Grenoble Cedex 9, France
Lancet 359:2188-94. 2002
..Private-sector research obligations should be explored, and a public-sector not-for-profit research and development capacity promoted...
Psychological trauma of the civil war in Sri LankaKaz de Jong
, Amsterdam, Netherlands
Lancet 359:1517-8. 2002
Generic medicines are not substandard medicinesNathan Ford
Lancet 359:1351; author reply 1351-2. 2002
Conflict in Sri Lanka. Sri Lanka's health service is a casualty of 20 years of warBrigg Reilley
, Colombo, Sri Lanka
BMJ 324:361. 2002
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and developmentPhilippe J Guerin
Norwegian Institute of Public Health, Norway
Lancet Infect Dis 2:564-73. 2002
..Evidence on these approaches should provide national governments and international donors with the cost-benefit information that would justify much-needed increases in global support for appropriate and effective malaria control...
Trade concerns must not be allowed to set the public health agendaNathan Ford
Lancet 361:71-2. 2003
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessmentLaurent Ferradini
Epicentre, Paris, France
Lancet 367:1335-42. 2006
..We aimed to assess the effectiveness of such a programme held by Médecins Sans Frontières (MSF) in the Chiradzulu district, Malawi...
Treatment of neuropathic pain in Sierra LeonePhillipe Lacoux
Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK
Lancet Neurol 1:190-5. 2002
..There have recently been no major treatment advances for neuropathic or phantom pain; however, the general body of knowledge about amputation pain can be increased by observations from these difficult settings...
DFID's health strategyGorik Ooms
Lancet 370:652-3. 2007
Trauma of Chechnya's ongoing war on internally displaced peopleKaz de Jong
Lancet 364:1008. 2004
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in CambodiaBart Janssens
Medecins Sans Frontieres, Phnom Penh, Cambodia
Pediatrics 120:e1134-40. 2007
..We aimed to describe the clinical, immunologic, and virologic outcomes of pediatric patients with >12 months of highly active antiretroviral therapy in 2 routine programs in Cambodia...
HIV and cytomegalovirus in ThailandArlene Chua
Lancet Infect Dis 5:328-9. 2005
When best practice is bad medicine: a new approach to rationing tertiary health services in South AfricaChris Kenyon
Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital, Cape Town
S Afr Med J 98:350, 352, 354 passim. 2008
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretroviralsJens Van Roey
Medecins Sans Frontieres, Campaign for Access to Essential Medecins, Rue de Lausanne 78, 1211 Geneva, Switzerland
Drug Discov Today 13:601-5. 2008
..Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority...
First-line and second-line antiretroviral therapyAlexandra Calmy
Lancet 364:329; author reply 330. 2004